Clinical Trials Directory

Trials / Terminated

TerminatedNCT00823472

Trial Comparing Start Stimulation of Recombinant Follicle Stimulating Hormone (rFSH) on Cycle Day 2 Versus Cycle Day 5 in In Vitro Fertilization (IVF)

Among IVF Patients Undergoing Fixed Antagonist Protocols With Recombinant FSH, Does Administration of Recombinant FSH From Cycle Day 5 Onwards Compared With Cycle Day 2 Onwards, Yield a Higher Number of Good Quality Embryos?

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
147 (actual)
Sponsor
UMC Utrecht · Academic / Other
Sex
Female
Age
18 Years – 36 Years
Healthy volunteers
Accepted

Summary

Background of the study: Milder stimulation protocols have the advantage of being less expensive and more patient-friendly. Moreover, recent evidence suggests that mild stimulation protocols lead to lower embryo aneuploidy rates compared to conventional treatment regimens. Although with mild stimulation protocols the expected number of oocytes retrieved will be lower, pregnancy rates have shown to be similar possibly because embryo quality outfavours embryo quantity. Objective of the study: The aim of the study is to determine whether cycle day (CD) 5 start of stimulation will lead to better quality of embryos, based on morphology, than CD 2 start, in IVF with GnRH antagonist co-treatment started on a fixed day. Study design: Prospective randomized trial comparing two different starting days of ovarium stimulation (day 2 versus day 5) for IVF treatment. Intervention: One group wil start on cycle day 2 with stimulation of the ovaries with recombinant FSH. The other group will start on cycle day 5. Both group will start suppressing the gonadotrophin production of the the pituitary gland on cycle day 6 with a GnRH antagonist. Primary study parameters/outcome of the study: Primary outcome parameter is number of top embryos per ovum pick up. Secondary study parameters/outcome of the study: Secondary outcome measures are duration of stimulation, cancellation rate, fertilization rate, number of cumulus oocyte complexes obtained, number of mature oocytes obtained, number of top embryos per started cycle, amount of IU recFSH, and clinical pregnancy rate.

Conditions

Interventions

TypeNameDescription
DRUGMild stimulationFixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm

Timeline

Start date
2009-01-01
Primary completion
2010-10-01
Completion
2010-10-01
First posted
2009-01-15
Last updated
2019-01-29
Results posted
2010-12-02

Locations

2 sites across 2 countries: Belgium, Netherlands

Source: ClinicalTrials.gov record NCT00823472. Inclusion in this directory is not an endorsement.